socalTECH
APRIL 29, 2021
Thousand Oaks-based Capsida Biotherapeutics, a new biotechnology company focused on using adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases, has uncloaked from stealth mode, saying it has raised $140M in total capital.
socalTECH
JANUARY 5, 2017
the founding shareholder and chairman and treasurer of Thousand Oaks-based Amgen , has died, at the age of 90. Bowes--who also founded venture capital firm USVP --died peacefully in his home on December 28th. USVP has backed such companies as Sun Microsystems, New Focus, Check Point Software Technologies, and hundreds of others.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
socalTECH
OCTOBER 12, 2016
Thousand Oaks-based Akriveia Therapeutics , a biotechnology startup focused on immuno-oncology, announced this morning that it has raised $7.5M The investment came from F-Prime Capital Partners. in a Series A investment. As part of the funding, F-Prime's Thomas Beck and Ben Auspitz have joined the company's board.
socalTECH
OCTOBER 9, 2015
Thousand Oaks-based Amgen has seen an exit out of its startup investment portfolio, and activities of its Amgen Ventures venture capital arm, at Berkeley-based Adheron Therapeutics this morning. Adheron said that it has been acquired by Roche , in a deal worth $105M upfront and up to $475M in additional milestone payments.
socalTECH
APRIL 20, 2017
Thousand Oaks-based wireless networking equipment maker Xirrus has been acquired by Riverbed , to help bolster its SD WAN efforts, the two said on Wednesday. Financial terms of the acquisition were not announced. Riverbed said it will continue to offer up Xirrus as a stand-alone enterprise WLAN solution. READ MORE>>.
socalTECH
NOVEMBER 7, 2013
Thousand Oaks-based ImmunGene , a startup biotech company developing antibody-based, protein therapeutics for treating cancer, said today that it has raised $9M in a Series A funding, to advance its early stage development products. immungene venture capital biotech biotechnology cancer therapeutics' to its board of directors.
socalTECH
OCTOBER 5, 2015
Thousand Oaks-based Teledyne Technologies said this morning that it is cutting its outlook for the third quarter and full year, due to decline in sales in energy-related products. dollar and "challenging" capital spending environment impacting its results. The company also blamed a strong U.S. READ MORE>>.
Expert insights. Personalized for you.
113 
Let's personalize your content